H. Steel

The Innovative Medicines Initiative's New Drugs for Bad Bugs programme: European public-private partnerships for the development of new strategies to tackle antibiotic resistance.

H. Goossens, M. Bonten, H. Jafri, 2016, The Journal of antimicrobial chemotherapy.

Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial.

S. Hammer, J. Montaner, D. Cooper, 2001, JAMA.

A dose‐ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment‐naive subjects

T. Harrer, C. Katlama, S. Staszewski, 1998, AIDS.

Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir.

O. Naderer, G. Pearce, H. Steel, 2001, Clinical therapeutics.

Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. The EuroGUidelines Group for HIV resistance.

Soriano, K. Hertogs, F. Brun-Vézinet, 2001, AIDS.

Antiviral Efficacy of Abacavir in Antiretroviral Therapy-Experienced Adults Harbouring HIV-1 with Specific Patterns of Resistance to Nucleoside Reverse Transcriptase Inhibitors

S. Hetherington, G. Pearce, W. Spreen, 2004, Antiviral therapy.

Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative Group.

J W Mulder, R. Schooley, P. Harrigan, 1996, The Journal of infectious diseases.

The abacavir hypersensitivity reaction and interruptions in therapy.

W. Powell, S. Hetherington, H. Steel, 2001, AIDS.